退伍军人肝硬化合并阿片类使用障碍的药物治疗
本研究基于退伍军人健康管理局数据库,纳入5600例肝硬化合并活跃阿片类使用障碍(OUD)的退伍军人,评估美沙酮或丁丙诺啡的起始治疗及相关因素与结局。结果显示仅13%在180天内接受药物治疗(MOUD),年龄、丙肝感染及其他物质使用障碍与MOUD正相关,酒精使用障碍、阿片类处方及精神分裂症与MOUD负相关。MOUD与死亡率或新发肝失代偿无显著关联。
要点
- 肝硬化合并活跃OUD的退伍军人中仅13%在180天内启动MOUD。
- 酒精使用障碍、精神分裂症及既往阿片类处方与MOUD启动负相关。
- MOUD与死亡率或新发肝失代偿无显著关联。
核心结论
- 肝硬化合并活跃OUD的退伍军人中MOUD使用率低,且特定亚组(酒精使用障碍、精神分裂症、既往阿片类处方)更少接受MOUD。
研究设计与样本
- 基于退伍军人健康管理局企业数据仓库构建的回顾性队列,纳入5600例肝硬化合并活跃OUD的退伍军人,随访180天评估MOUD启动及相关因素与结局。
主要发现
- 722例(13%)在180天内接受MOUD(美沙酮或丁丙诺啡)。
- MOUD与年龄(AOR 1.04,95%CI 1.01-1.07)、丙肝(AOR 2.15,95%CI 1.37-3.35)及其他物质使用障碍(AOR 1.47,95%CI 1.05-2.04)正相关。
- MOUD与酒精使用障碍(AOR 0.70,95%CI 0.52-0.95)、阿片类处方(AOR 0.51,95%CI 0.38-0.70)及精神分裂症(AOR 0.59,95%CI 0.37-0.95)负相关。
- MOUD与死亡率(aHR 1.20,95%CI 0.95-1.52)及新发肝失代偿(OR 0.57,95%CI 0.30-1.09)无显著关联。
临床怎么用
- 对肝硬化合并OUD的退伍军人应常规评估MOUD启动必要性,尤其关注酒精使用障碍、精神分裂症及既往阿片类处方者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Although opioid use disorder (OUD) is common in patients with cirrhosis, it is unclear how medication treatment for OUD (MOUD) is used in this population. We aimed to assess the factors associated with MOUD and mortality in a cohort of Veterans with cirrhosis and OUD. METHODS: Within the Veterans Health Administration Corporate Data Warehouse, we developed a cohort of Veterans with cirrhosis and active OUD, using 2 outpatient or 1 inpatient International Classification of Diseases, ninth revision codes from 2011 to 2015 to define each condition. We assessed MOUD initiation with methadone or buprenorphine over the 180 days following the first OUD International Classification of Diseases, ninth revision code in the study period. We fit multivariable regression models to assess the association of sociodemographic and clinical factors with receiving MOUD and the associations between MOUD and subsequent clinical outcomes, including new hepatic decompensation and mortality. RESULTS: Among 5,600 Veterans meeting criteria for active OUD and cirrhosis, 722 (13%) were prescribed MOUD over 180 days of follow-up. In multivariable modeling, MOUD was significantly, positively associated with age (adjusted odds ratio [AOR] per year: 1.04, 95% confidence interval (CI): 1.01-1.07), hepatitis C virus (AOR = 2.15, 95% CI = 1.37-3.35), and other substance use disorders (AOR = 1.47, 95% CI = 1.05-2.04) negatively associated with alcohol use disorder (AOR = 0.70, 95% CI = 0.52-0.95), opioid prescription (AOR = 0.51, 95% CI = 0.38-0.70), and schizophrenia (AOR = 0.59, 95% CI = 0.37-0.95). MOUD was not significantly associated with mortality (adjusted hazards ratio = 1.20, 95% CI = 0.95-1.52) or new hepatic decompensation (OR = 0.57, CI = 0.30-1.09). DISCUSSION: Few Veterans with active OUD and cirrhosis received MOUD, and those with alcohol use disorder, schizophrenia, and previous prescriptions for opioids were least likely to receive these effective therapies.
引用
- Rogal S, Youk A, Agbalajobi O, et al. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis. Am J Gastroenterol. 2021. PMID: 33811202. doi:10.14309/ajg.0000000000001228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。